TomoTherapy co-founder Reckwerdt retires

TriMed Staff | | Health Imaging | Artificial Intelligence
TomoTherapy has announced that co-founder Paul J. Reckwerdt will retire as president and relinquish his board directorship, effective Dec. 31.

Reckwerdt plans to pursue entrepreneurial opportunities and will serve as a strategic advisor to Compact Particle Acceleration Corporation, which is developing a compact proton therapy system in partnership with TomoTherapy.

Reckwerdt co-founded TomoTherapy with Rock Mackie, PhD, to commercialize a precise form of radiation therapy that the two researched at University of Wisconsin in Madison.

TriMed Staff

Related Content

AI beats standard regression models at predicting lung cancer risk
AI reduces CT lung cancer screening workload by nearly 80%
How AI and CCTA help heart teams plan ahead before PCI
5 steps for evaluating radiology AI applications
Adaptable AI system detects subtle changes in imaging, has potential across multiple clinical settings
New algorithm models radiologists' eye movements to interpret chest X-rays

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.